Developer docs
API playgroundTry for free, no card

Search company profiles

Lepu Bio

Full company profile

uuid0002fx6

Namestring
Lepu Bio
Legal namestring
Lepu Biopharma Co., Ltd.
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Lepu Biopharma Co., Ltd. (HKEX: 02157.HK) is an innovation-driven biopharmaceutical company headquartered in Shanghai, China, focused on developing oncology therapeutics to address unmet medical needs in cancer treatment. Founded in January 2018 by Dr. Pu Zhongjie as the biotech arm of Lepu Medical, the company operates three proprietary technology platforms: an ADC (Antibody-Drug Conjugate) technology platform covering end-to-end R&D and cGMP manufacturing, an antibody discovery platform featuring a 10^11-scale full human naive antibody library using phage display technology (enabling 4-6 week antibody development versus 4-6 months for traditional hybridoma), and an advanced process and analytical development platform for GMP-compliant cell bank construction and biopharmaceutical characterization.

The company's commercial portfolio includes two approved products: MEIYOUHENG (Becotatug Vedotin Injection), the first EGFR-targeted ADC approved in China (NMPA approval October 2025) for recurrent/metastatic nasopharyngeal cancer, and PUYOUHENG (Pucotenlimab Injection), an anti-PD-1 monoclonal antibody approved in 2022 for MSI-H/dMMR advanced solid tumors and unresectable/metastatic melanoma. The clinical-stage pipeline comprises seven drug candidates, six of which are ADCs targeting EGFR, HER2, CD20, GPC3, CDH17, and tissue factor, plus an oncolytic virus candidate (CG0070) licensed from CG Oncology.

Lepu Biopharma generates revenue through three channels: (1) direct product sales in China via dedicated sales and marketing forces distributing through hospitals and pharmacies, (2) international licensing and milestone payments from out-licensing deals, most notably with AstraZeneca for CMG901 (Claudin 18.2 ADC, up to $1.1B in milestones) and ArriVent for MRG007 (CDH17 ADC, $47M upfront plus up to $1.16B in milestones), and (3) contract development and manufacturing (CDMO) services leveraging its 2,000L GMP-compliant Beijing facility. The company reported 2025 revenue of RMB 935 million (~2.5x year-on-year growth) and achieved its first annual net profit of RMB 261 million, supported by a portfolio of 55+ issued patents globally and a manufacturing footprint spanning an operational Beijing plant plus Shanghai Biotech Park Phase 1 capacity of 12,000L (6,000L line under construction).

Short descriptiontext

Lepu Biopharma is a Shanghai-based, Hong Kong-listed (02157.HK) oncology biopharmaceutical company developing ADC and immuno-oncology therapeutics, with two NMPA-approved commercial products (MEIYOUHENG and PUYOUHENG), seven clinical-stage ADC candidates, and global licensing partnerships with AstraZeneca and ArriVent.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersThe Woodlands, United States
HQ citystring
The Woodlands
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibody-drug conjugates, oncology therapeutics, monoclonal antibodies, biopharmaceutical development, clinical-stage drug pipeline
Industry4 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Oncology Biopharmaceuticals
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales (China)
TypeHardware Sales
Description

Commercial sales of approved drugs in China including MEIYOUHENG (Becotatug Vedotin Injection) for R/M NPC and PUYOUHENG (Pucotenlimab Injection) for MSI-H/dMMR solid tumors and melanoma.

en.lepubiopharma.com
2Licensing and Milestone Payments
TypeLicensing Royalties
Description

International licensing deals generating upfront payments, development milestones, regulatory milestones, and sales milestones plus tiered royalties. Examples: MRG007 deal with ArriVent ($47M upfront + up to $1.16B milestones); CMG901 deal with AstraZeneca (up to $1.1B milestones).

en.lepubiopharma.com
3CDMO Services
TypeProfessional Services
Description

Contract development and manufacturing organization services leveraging Beijing 2,000L GMP-compliant production line for clinical drug supply and third-party CDMO production.

en.lepubiopharma.com
4Product Revenue (2025)
TypeHardware Sales
Description

2025 annual results showed revenue of 935 million yuan with first annual net profit of 261 million yuan, demonstrating transition to profitability.

phirda.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details1 tier
1MEIYOUHENG (Becotatug Vedotin Injection) - approved for R/M NPC treatment
ModelOtherBilling cadencePay-as-you-go
Notes

Product pricing not publicly disclosed; distributed through hospital and pharmacy channels in China following NMPA approval.

en.lepubiopharma.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Trispecific Antibody T Cell Engager Platform
Description

A platform utilizing protein binding domains such as nanobodies and scFv to augment T cells' response to solid tumors

en.lepubiopharma.com
+1 more record
Core offering1 text field

Lepu Biopharma is an innovation-driven biopharmaceutical company developing oncology therapeutics including antibody-drug conjugates (ADCs), monoclonal antibodies, and oncolytic viruses. The company operates three proprietary technology platforms and has two commercial-stage products (MEIYOUHENG/Becotatug Vedotin and PUYOUHENG/Pucotenlimab) approved in China, along with multiple clinical-stage candidates for solid tumors and hematological malignancies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • MEIYOUHENG combination therapy showed 73.3% cORR and 10.9 months mPFS in R/M NPC patients after failed IO and platinum therapy
+4 more records
Product overview1 text field

Lepu Biopharma is an innovation-driven biopharmaceutical company focused on oncology therapeutics. The company operates three technology platforms (ADC technology platform, antibody discovery platform, and advanced process/analytical development platform) to develop its pipeline of drug candidates. The commercial-stage products include MEIYOUHENG (Becotatug Vedotin Injection), the first EGFR-targeted ADC approved in China, and PUYOUHENG (Pucotenlimab Injection), an anti-PD-1 monoclonal antibody approved for MSI-H/dMMR solid tumors and melanoma. The clinical-stage pipeline comprises multiple ADCs (MRG003, MRG004A, MRG002, MRG001, MRG006A), immunotherapies (LP002, CTM012), and an oncolytic virus (CG0070). Several assets have been out-licensed to global partners including CMG901 (AstraZeneca) and MRG007 (ArriVent BioPharma).

Product and service8 records
1MEIYOUHENG (Becotatug Vedotin Injection)
CategoryCommercial ADC Drug
Description

An EGFR-targeted antibody-drug conjugate (ADC) consisting of an EGFR-targeted monoclonal antibody conjugated with monomethyl auristatin E via valine-citrulline linker. Approved in China for treatment of recurrent or metastatic nasopharyngeal cancer patients who have failed standard therapies.

2PUYOUHENG (Pucotenlimab Injection)
CategoryCommercial Immunotherapy Drug
Description

A humanized IgG4 anti-PD-1 monoclonal antibody with extended half-life via triple mutations in Fc region. Approved in China for MSI-H/dMMR advanced solid tumors and unresectable or metastatic melanoma.

3MRG003
CategoryClinical Stage ADC Drug Candidate
Description

EGFR-targeted ADC conjugated with monomethyl auristatin E via valine-citrulline linker. In clinical development for nasopharyngeal cancer, head and neck squamous cell carcinoma, and other EGFR-positive solid tumors.

4MRG004A
CategoryClinical Stage ADC Drug Candidate
Description

Tissue factor (TF)-targeted ADC with site-specific conjugation technology. Granted FDA Orphan-Drug Designation and Fast Track Designation for pancreatic cancer treatment.

5CMG901
CategoryLicensed ADC Drug Candidate
Description

Claudin 18.2-targeted ADC consisting of anti-CLDN18.2 monoclonal antibody, protease-degradable linker, and MMAE cytotoxic payload. Potential first-in-class Claudin 18.2 ADC for gastrointestinal cancers, globally licensed to AstraZeneca.

6MRG002
CategoryClinical Stage ADC Drug Candidate
Description

HER2-targeted ADC for treatment of HER2-positive breast cancer and HER2 over-expressing cancers with liver metastasis.

7MRG001
CategoryClinical Stage ADC Drug Candidate
Description

CD20-targeted ADC in clinical development for non-Hodgkin's lymphoma (NHL).

8MRG006A
Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Excalipoint Therapeutics
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-03-18
Description

Excalipoint licensed two antibody programs from Lepu Biopharma for $10 million upfront as part of their trispecific antibody development for cancer and autoimmune diseases.

cen.acs.org
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-01-22
Description

Exclusive licensing agreement for MRG007 (CDH17-targeted ADC for GI cancers). Lepu Biopharma grants exclusive rights outside Greater China. Receives $47M upfront and is eligible for up to $1.16B in development, regulatory and sales milestones plus tiered royalties on net sales. First IND submission planned for H1 2025 with focus on colorectal, pancreatic and other GI cancers.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-22
Description

Joint venture (30% Lepu Biopharma, 70% Keymed) holding rights to CMG901. AstraZeneca partnership transacted through KYM for global license.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-02-23
Description

Global exclusive license agreement for CMG901 (Claudin 18.2 ADC). AstraZeneca responsible for global research, development, manufacturing and commercialization. KYM Biosciences (joint venture of Lepu Biopharma 30% and Keymed 70%) receives up to $1.1B in milestones and tiered royalties up to low double-digits. Transaction closed H1 2023.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-02-23
Description

Joint venture KYM Biosciences Inc. established with Keymed (70% ownership) and Lepu Biopharma (30% ownership) for co-development of CMG901 Claudin 18.2 ADC. Both parties collaborate on global development while Lepu contributes manufacturing and development capabilities.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-03-05
Description

Licensed CG0070 oncolytic virus antineoplastic drug for product development rights and global supply rights in China. CG0070 is a genetically modified adenovirus type 5 with cancer-selective E2F-1 promoter and GM-CSF gene for tumor-selective replication and lysis.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-10-21
Description

Scientific research cooperation for construction of fully human antibody library and development of high-throughput screening technology for antibody drugs. CtM Bio (Lepu Biopharma subsidiary) collaboration with Shanghai Institute for Advanced Immunochemical Studies.

Strategic tierCoreTypeTechnology or Integration
Description

Non-exclusive licensing of ADC platform technologies including fused cyclooctyne compounds, glycosyltransferase enzymes, modified antibody conjugation processes, and sulfamide linker technologies for ADC development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Joint development partner for MRG004A tissue factor-targeted ADC along with Miracogen Shanghai and SIMMCAS, holding all rights in Mainland China and joint development in U.S. and Japan.

Strategic tierMinorTypeOthers
Description

U.S. subsidiary office in The Woodlands, Texas for overseas operations and potential U.S. market development.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Chinese biopharmaceutical company developing a pipeline of ADCs (e.g., Disitamab Vedotin) and antibody-based oncology therapeutics. Directly comparable to Lepu Bio as another China-based ADC-focused innovator with approved and clinical-stage assets.

TypeEmerging player
Description

Clinical-stage biopharma that licensed MRG007 from Lepu Bio for development outside Greater China. Comparable as an emerging ADC-focused player commercializing assets originating from the same China innovation ecosystem.

TypeDirect peer
Description

Hong Kong-listed Chinese pharma with an oncology biologics pipeline including ADCs and monoclonal antibodies. Comparable as a large-scale domestic competitor developing novel oncology biologics for the China market.

TypeBroad incumbent
Description

Japanese pharma and global ADC leader (Enhertu, Dato-DXd). Comparable as the dominant ADC platform innovator whose partnerships (e.g., with AstraZeneca) define the competitive landscape Lepu Bio operates in.

TypeBroad incumbent
Description

Global pharma partner that licensed CMG901 from Lepu Bio and is the leader in ADC commercialization. Comparable as both a partner and the global benchmark for ADC commercial execution that Lepu's pipeline must compete against.

TypeDirect peer
Description

China-based biopharmaceutical company with commercialized oncology biologics (PD-1, etc.) and a growing pipeline of ADCs and bispecifics. Comparable business model combining domestic commercialization with global partnership deals.

TypeDirect peer
Description

China-based biotech developing bispecific antibodies and ADCs. Keymed's strategic partner, with comparable platform technology and pipeline in immuno-oncology.

8Hansoh Pharmaceutical Group
TypeDirect peer
Description

Major Chinese pharma with growing ADC and oncology biologics pipeline. Comparable in therapeutic area focus (oncology) and biologics manufacturing scale, with overlapping targets in ADC development.

TypeBroad incumbent
Description

Global China-headquartered oncology biopharmaceutical with a commercial-stage PD-1 (Tislelizumab) and broad hematology/oncology pipeline. Comparable as a larger incumbent in China oncology biologics with global commercial reach.

TypeDirect peer
Description

Hong Kong-listed biotech and Lepu's joint venture partner in KYM Biosciences (KYM holds 70%, Lepu 30%). Comparable as a clinical-stage Chinese biotech developing novel oncology antibodies and ADCs with global pharma partnerships.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lepu Bio

Oncology Biopharmaceuticalsen.lepubiopharma.com

Lepu Biopharma is a Shanghai-based, Hong Kong-listed (02157.HK) oncology biopharmaceutical company developing ADC and immuno-oncology therapeutics, with two NMPA-approved commercial products (MEIYOUHENG and PUYOUHENG), seven clinical-stage ADC candidates, and global licensing partnerships with AstraZeneca and ArriVent.

What Lepu Bio does

Lepu Biopharma Co., Ltd. (HKEX: 02157.HK) is an innovation-driven biopharmaceutical company headquartered in Shanghai, China, focused on developing oncology therapeutics to address unmet medical needs in cancer treatment. Founded in January 2018 by Dr. Pu Zhongjie as the biotech arm of Lepu Medical, the company operates three proprietary technology platforms: an ADC (Antibody-Drug Conjugate) technology platform covering end-to-end R&D and cGMP manufacturing, an antibody discovery platform featuring a 10^11-scale full human naive antibody library using phage display technology (enabling 4-6 week antibody development versus 4-6 months for traditional hybridoma), and an advanced process and analytical development platform for GMP-compliant cell bank construction and biopharmaceutical characterization.

The company's commercial portfolio includes two approved products: MEIYOUHENG (Becotatug Vedotin Injection), the first EGFR-targeted ADC approved in China (NMPA approval October 2025) for recurrent/metastatic nasopharyngeal cancer, and PUYOUHENG (Pucotenlimab Injection), an anti-PD-1 monoclonal antibody approved in 2022 for MSI-H/dMMR advanced solid tumors and unresectable/metastatic melanoma. The clinical-stage pipeline comprises seven drug candidates, six of which are ADCs targeting EGFR, HER2, CD20, GPC3, CDH17, and tissue factor, plus an oncolytic virus candidate (CG0070) licensed from CG Oncology.

Lepu Biopharma generates revenue through three channels: (1) direct product sales in China via dedicated sales and marketing forces distributing through hospitals and pharmacies, (2) international licensing and milestone payments from out-licensing deals, most notably with AstraZeneca for CMG901 (Claudin 18.2 ADC, up to $1.1B in milestones) and ArriVent for MRG007 (CDH17 ADC, $47M upfront plus up to $1.16B in milestones), and (3) contract development and manufacturing (CDMO) services leveraging its 2,000L GMP-compliant Beijing facility. The company reported 2025 revenue of RMB 935 million (~2.5x year-on-year growth) and achieved its first annual net profit of RMB 261 million, supported by a portfolio of 55+ issued patents globally and a manufacturing footprint spanning an operational Beijing plant plus Shanghai Biotech Park Phase 1 capacity of 12,000L (6,000L line under construction).

Lepu Bio firmographics

Firmographics
Name
Lepu Bio
Legal name
Lepu Biopharma Co., Ltd.
Website
https://en.lepubiopharma.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Lepu Biopharma is a Shanghai-based, Hong Kong-listed (02157.HK) oncology biopharmaceutical company developing ADC and immuno-oncology therapeutics, with two NMPA-approved commercial products (MEIYOUHENG and PUYOUHENG), seven clinical-stage ADC candidates, and global licensing partnerships with AstraZeneca and ArriVent.
Ownership category
akta.pro rank

Lepu Bio industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAACAM
Gene Therapy Regulatory, Pharmacovigilance & Clinical Operations Services
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Antibody-drug conjugates
  • Oncology therapeutics
  • Monoclonal antibodies
  • Biopharmaceutical development
  • Clinical-stage drug pipeline

Where Lepu Bio is headquartered

Location

Headquarters

HQ city
The Woodlands
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Lepu Bio business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Product Sales (China): Commercial sales of approved drugs in China including MEIYOUHENG (Becotatug Vedotin Injection) for R/M NPC and PUYOUHENG (Pucotenlimab Injection) for MSI-H/dMMR solid tumors and melanoma.
  2. Licensing and Milestone Payments: International licensing deals generating upfront payments, development milestones, regulatory milestones, and sales milestones plus tiered royalties. Examples: MRG007 deal with ArriVent ($47M upfront + up to $1.16B milestones); CMG901 deal with AstraZeneca (up to $1.1B milestones).
  3. CDMO Services: Contract development and manufacturing organization services leveraging Beijing 2,000L GMP-compliant production line for clinical drug supply and third-party CDMO production.
  4. Product Revenue (2025): 2025 annual results showed revenue of 935 million yuan with first annual net profit of 261 million yuan, demonstrating transition to profitability.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goMEIYOUHENG (Becotatug Vedotin Injection) - approved for R/M NPC treatment

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Lepu Bio product offering

Product offering

Core offering

Lepu Biopharma is an innovation-driven biopharmaceutical company developing oncology therapeutics including antibody-drug conjugates (ADCs), monoclonal antibodies, and oncolytic viruses. The company operates three proprietary technology platforms and has two commercial-stage products (MEIYOUHENG/Becotatug Vedotin and PUYOUHENG/Pucotenlimab) approved in China, along with multiple clinical-stage candidates for solid tumors and hematological malignancies.

Product overview

Lepu Biopharma is an innovation-driven biopharmaceutical company focused on oncology therapeutics. The company operates three technology platforms (ADC technology platform, antibody discovery platform, and advanced process/analytical development platform) to develop its pipeline of drug candidates. The commercial-stage products include MEIYOUHENG (Becotatug Vedotin Injection), the first EGFR-targeted ADC approved in China, and PUYOUHENG (Pucotenlimab Injection), an anti-PD-1 monoclonal antibody approved for MSI-H/dMMR solid tumors and melanoma. The clinical-stage pipeline comprises multiple ADCs (MRG003, MRG004A, MRG002, MRG001, MRG006A), immunotherapies (LP002, CTM012), and an oncolytic virus (CG0070). Several assets have been out-licensed to global partners including CMG901 (AstraZeneca) and MRG007 (ArriVent BioPharma).

Differentiator

Problem solved

Functional benefit

Brands

  • Trispecific Antibody T Cell Engager Platform: A platform utilizing protein binding domains such as nanobodies and scFv to augment T cells' response to solid tumors
  • ADC Technology Platform

Products and services

  • MEIYOUHENG (Becotatug Vedotin Injection) An EGFR-targeted antibody-drug conjugate (ADC) consisting of an EGFR-targeted monoclonal antibody conjugated with monomethyl auristatin E via valine-citrulline linker. Approved in China for treatment of recurrent or metastatic nasopharyngeal cancer patients who have failed standard therapies.
  • PUYOUHENG (Pucotenlimab Injection) A humanized IgG4 anti-PD-1 monoclonal antibody with extended half-life via triple mutations in Fc region. Approved in China for MSI-H/dMMR advanced solid tumors and unresectable or metastatic melanoma.
  • MRG003 EGFR-targeted ADC conjugated with monomethyl auristatin E via valine-citrulline linker. In clinical development for nasopharyngeal cancer, head and neck squamous cell carcinoma, and other EGFR-positive solid tumors.
  • MRG004A Tissue factor (TF)-targeted ADC with site-specific conjugation technology. Granted FDA Orphan-Drug Designation and Fast Track Designation for pancreatic cancer treatment.
  • CMG901 Claudin 18.2-targeted ADC consisting of anti-CLDN18.2 monoclonal antibody, protease-degradable linker, and MMAE cytotoxic payload. Potential first-in-class Claudin 18.2 ADC for gastrointestinal cancers, globally licensed to AstraZeneca.
  • MRG002 HER2-targeted ADC for treatment of HER2-positive breast cancer and HER2 over-expressing cancers with liver metastasis.
  • MRG001 CD20-targeted ADC in clinical development for non-Hodgkin's lymphoma (NHL).
  • MRG006A

Quantifiable outcome

  • MEIYOUHENG combination therapy showed 73.3% cORR and 10.9 months mPFS in R/M NPC patients after failed IO and platinum therapy
  • +4 more outcomes

Companies that use Lepu Bio

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Lepu Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Lepu Bio partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered minor, core and flagship.

  • Excalipoint TherapeuticsminorOEM/ Whitelabel/ Licensing Partner · 18 March 2026Excalipoint licensed two antibody programs from Lepu Biopharma for $10 million upfront as part of their trispecific antibody development for cancer and autoimmune diseases.
  • ArriVent BioPharma (Nasdaq: AVBP)coreOEM/ Whitelabel/ Licensing Partner · 22 January 2025Exclusive licensing agreement for MRG007 (CDH17-targeted ADC for GI cancers). Lepu Biopharma grants exclusive rights outside Greater China. Receives $47M upfront and is eligible for up to $1.16B in development, regulatory and sales milestones plus tiered royalties on net sales. First IND submission planned for H1 2025 with focus on colorectal, pancreatic and other GI cancers.
  • KYM Biosciences Inc.flagshipStrategic or Co-development Partner · 22 January 2025Joint venture (30% Lepu Biopharma, 70% Keymed) holding rights to CMG901. AstraZeneca partnership transacted through KYM for global license.
  • AstraZeneca (LSE/STO/Nasdaq: AZN)flagshipOEM/ Whitelabel/ Licensing Partner · 23 February 2023Global exclusive license agreement for CMG901 (Claudin 18.2 ADC). AstraZeneca responsible for global research, development, manufacturing and commercialization. KYM Biosciences (joint venture of Lepu Biopharma 30% and Keymed 70%) receives up to $1.1B in milestones and tiered royalties up to low double-digits. Transaction closed H1 2023.
  • Keymed Biosciences Inc. (Stock Code: 02162.HK)flagshipStrategic or Co-development Partner · 23 February 2023Joint venture KYM Biosciences Inc. established with Keymed (70% ownership) and Lepu Biopharma (30% ownership) for co-development of CMG901 Claudin 18.2 ADC. Both parties collaborate on global development while Lepu contributes manufacturing and development capabilities.
  • CG Oncology, Inc. (USA)coreOEM/ Whitelabel/ Licensing Partner · 5 March 2021Licensed CG0070 oncolytic virus antineoplastic drug for product development rights and global supply rights in China. CG0070 is a genetically modified adenovirus type 5 with cancer-selective E2F-1 promoter and GM-CSF gene for tumor-selective replication and lysis.
  • ShanghaiTech University - SIAISminorStrategic or Co-development Partner · 21 October 2020Scientific research cooperation for construction of fully human antibody library and development of high-throughput screening technology for antibody drugs. CtM Bio (Lepu Biopharma subsidiary) collaboration with Shanghai Institute for Advanced Immunochemical Studies.
  • SynaffixcoreTechnology or IntegrationNon-exclusive licensing of ADC platform technologies including fused cyclooctyne compounds, glycosyltransferase enzymes, modified antibody conjugation processes, and sulfamide linker technologies for ADC development.
  • Fudan UniversityminorStrategic or Co-development PartnerJoint development partner for MRG004A tissue factor-targeted ADC along with Miracogen Shanghai and SIMMCAS, holding all rights in Mainland China and joint development in U.S. and Japan.
  • InnoCube Biosciences Inc.minorOthersU.S. subsidiary office in The Woodlands, Texas for overseas operations and potential U.S. market development.

Scale indicators17 records

Recent moves11 records

Expansion highlights2 records

Lepu Bio competitors and assessment

Company assessment

Direct peers

  • RemeGen Co., Ltd. Chinese biopharmaceutical company developing a pipeline of ADCs (e.g., Disitamab Vedotin) and antibody-based oncology therapeutics. Directly comparable to Lepu Bio as another China-based ADC-focused innovator with approved and clinical-stage assets.
  • CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharma with an oncology biologics pipeline including ADCs and monoclonal antibodies. Comparable as a large-scale domestic competitor developing novel oncology biologics for the China market.
  • Innovent Biologics: China-based biopharmaceutical company with commercialized oncology biologics (PD-1, etc.) and a growing pipeline of ADCs and bispecifics. Comparable business model combining domestic commercialization with global partnership deals.
  • Akeso, Inc. China-based biotech developing bispecific antibodies and ADCs. Keymed's strategic partner, with comparable platform technology and pipeline in immuno-oncology.
  • Hansoh Pharmaceutical Group: Major Chinese pharma with growing ADC and oncology biologics pipeline. Comparable in therapeutic area focus (oncology) and biologics manufacturing scale, with overlapping targets in ADC development.
  • Keymed Biosciences: Hong Kong-listed biotech and Lepu's joint venture partner in KYM Biosciences (KYM holds 70%, Lepu 30%). Comparable as a clinical-stage Chinese biotech developing novel oncology antibodies and ADCs with global pharma partnerships.

Emerging players

  • ArriVent BioPharma: Clinical-stage biopharma that licensed MRG007 from Lepu Bio for development outside Greater China. Comparable as an emerging ADC-focused player commercializing assets originating from the same China innovation ecosystem.

Broad incumbents

  • Daiichi Sankyo: Japanese pharma and global ADC leader (Enhertu, Dato-DXd). Comparable as the dominant ADC platform innovator whose partnerships (e.g., with AstraZeneca) define the competitive landscape Lepu Bio operates in.
  • AstraZeneca: Global pharma partner that licensed CMG901 from Lepu Bio and is the leader in ADC commercialization. Comparable as both a partner and the global benchmark for ADC commercial execution that Lepu's pipeline must compete against.
  • BeiGene: Global China-headquartered oncology biopharmaceutical with a commercial-stage PD-1 (Tislelizumab) and broad hematology/oncology pipeline. Comparable as a larger incumbent in China oncology biologics with global commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Lepu Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lepu Bio leadership team

Management profile

Number of profiles

Profiles10 records

Lepu Bio subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Lepu Bio funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lepu Bio M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lepu Bio

What does Lepu Bio do?

Lepu Biopharma is an innovation-driven biopharmaceutical company developing oncology therapeutics including antibody-drug conjugates (ADCs), monoclonal antibodies, and oncolytic viruses. The company operates three proprietary technology platforms and has two commercial-stage products (MEIYOUHENG/Becotatug Vedotin and PUYOUHENG/Pucotenlimab) approved in China, along with multiple clinical-stage candidates for solid tumors and hematological malignancies.

Is Lepu Bio a public or private company?

Lepu Bio is a public company. It is classified as public and is currently operating.

When was Lepu Bio founded?

Lepu Bio was founded in 2018. It employs 1 to 10 people.

Where is Lepu Bio based?

Lepu Bio is headquartered in The Woodlands, United States, in the North America region.

How does Lepu Bio make money?

Four revenue lines are on record. Product Sales (China) is the primary driver. The others are licensing and Milestone Payments, CDMO Services and product Revenue (2025).

Who are Lepu Bio's main competitors?

Direct peers on record are RemeGen Co., Ltd., CSPC Pharmaceutical Group, Innovent Biologics, Akeso, Inc., Hansoh Pharmaceutical Group and Keymed Biosciences. ArriVent BioPharma is listed as an emerging player. Broad incumbents are Daiichi Sankyo, AstraZeneca and BeiGene.

Does Lepu Bio have an API?

No public API is recorded for Lepu Bio.

What industry is Lepu Bio in?

Lepu Bio's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MoomooLepu Biopharma (02157): Clinical results of CMG901 (AZD0901) to be presented as a Late-Breaking Abstract (LBA) oral presentation at the Presidential Symposium during the 2026 ESMO Congress.Lepu Biopharma announced positive topline results from its Phase III trial of CMG901 (AZD0901) for CLDN18.2-positive advanced gastroesophageal cancer, showing overall survival benefits. The company also reported promising preliminary results from Phase I trials of MRG007 and MRG003, with a Phase II safety analysis showing a favorable profile.The future of tradingLepu Biopharma's CMG901 improves overall survival in Phase III gastroesophageal cancer trialLepu Biopharma presented Phase III CMG901 results at ESMO 2026, showing improved overall survival in previously treated advanced CLDN18.2-positive gastroesophageal cancer. CMG901 did not meet the statistical significance threshold for progression-free survival, but its safety profile was manageable. AstraZeneca owns CMG901, having licensed global development and commercialization rights in February 2023.Business & FinancialPD-1 NSCLC Pipeline 2026: MOA And ROA Insights, Clinical Trials Status, And Key Companies Involved By Delveinsight Genor Biopharma, Shandong Boan Biotech, Pfizer, Astrazeneca, Lepu Biopharma, GSKDelveInsight's 2026 report on PD-1 NSCLC pipeline covers clinical trial results, including a Phase III trial of ivonescimab showing improved overall survival versus pembrolizumab. It also notes AstraZeneca's discontinuation of a dual bispecific trial and Merck's Breakthrough Therapy designation for calderasib. The report profiles over 30 products from companies like Pfizer, AstraZeneca, and GSK.Stock TitanArriVent Q2 Results: $373M Cash Runway Into 2028ArriVent BioPharma reported its second-quarter 2026 financial results, highlighting a cash and investment runway of $373.1 million expected to fund operations into 2028. The company advanced its pipeline with the initiation of Phase 1b dose optimization for ADC lead ARR-217 in partnership with Lepu Biopharma and secured an exclusive licensing agreement with Shanghai Allist Pharmaceuticals for ARR-002 in Greater China. Topline pivotal Phase 3 data for firmonertinib is anticipated in the second half of 2026.LarepublicaAprobación de medicina contra el cáncer en China superaría a la de EE.UU.According to a study published in Health Affairs by researchers from the University of Pennsylvania and Friends of Cancer Research, China's National Medical Products Administration approved 94 new cancer drugs between 2020 and 2025, surpassing the 87 approved by the US FDA. China began outpacing the US in cancer drug approvals starting in 2023 and continued through 2025, despite the US still leading in first-in-class drugs (30 of 36) and reviewing applications 117 days faster on average. Three Chinese companies—BeBetter Med, Lepu Biopharma, and Chia Tai Tianqing Pharmaceutical Group (a subsidiary of Sino Biopharmaceutical)—developed pioneering cancer treatments that received approval, signaling China's rapid advancement in biopharmaceutical innovation from generic manufacturing to novel drug development.Phirda今日,又一中国 Biotech 在港交所上市Liang's IPO in Hong Kong opened at 22.6 HKD per share, raising about 1.28 billion HKD. The company, founded in 2018, has an 8-drug pipeline for chronic kidney disease, including AP301 and AP306 for high phosphorus. It plans to submit AP301's NMPA application in June 2026.PedailyInnovative drugs in the cold winter of MayThe Hang Seng Biotechnology Index fell in May, with 18A companies below HKD 1 billion rising to 12. Sangong reported a $950 million loss, and ADC pipelines faced setbacks, including Datroway's limited FDA approval. The article notes ADC production capacity scarcity and new payload innovations as potential growth drivers.PhirdaLepu Biotech, after crossing the profit watershedLepu Biotech reported its 2025 annual results, achieving revenue of 935 million yuan, representing approximately 2.5 times year-on-year growth, and recording its first annual net profit attributable to the parent company of 261 million yuan. The company also strengthened its balance sheet with cash reserves of 853 million yuan, more than double the previous year, while its adjusted net loss narrowed to about 31 million yuan, approaching breakeven. The article frames this as a critical turning point, indicating the company has reached a stage where it can generate self-sustaining growth.BioPharma DiveChinese biotech startup Excalipoint banks $69M for next-gen T cell engagersShanghai-based Excalipoint Therapeutics launched with $68.7 million in Series A financing and a portfolio of six antibody drugs targeting cancer and autoimmune diseases. The biotech is developing "trispecific" T cell engagers designed to address limitations of existing therapies, including difficulty targeting solid tumors and side effects like cytokine release syndrome, licensing two lead programs from Lepu Biopharma for $10 million upfront. Excalipoint, backed by 11 investors including HSG, Lilly Asia Ventures, and Eisai's venture arm, plans future partnership deals with multinational pharmaceutical companies outside China.Chemical & Engineering NewsShanghai start-up launches to develop trispecific antibodiesA Shanghai-based start-up, Excalipoint Therapeutics, has launched with $68.7 million in funding to develop trispecific antibodies for cancer and autoimmune diseases. The company has licensed two antibodies from Lepu Biopharma and plans to initiate clinical trials for its drug candidates targeting solid tumors. Excalipoint aims to leverage China's biotech infrastructure and demonstrate that Chinese founders can develop drugs for global markets.